The Trump administration announced 100% tariffs on imported brand-name drugs, while building in carveouts for drugmakers that strike most-favored nation-style agreements or pledge domestic manufacturing. Under the announced framework, some companies can reduce the rate to 20% if they commit to U.S. production, with other exemptions tied to trade relationships. In parallel, reporting indicates the administration is negotiating confidential pricing-and-manufacturing agreements to reduce tariff exposure. That approach keeps tariff risk focused on companies that do not reach negotiated deals. For biotech and pharma, the update is a direct cost and access overhang affecting supply chains, pricing strategy, and commercial planning—especially for smaller branded producers without existing manufacturing commitments.